Comparative Pharmacology
Head-to-head clinical analysis: XYLOCAINE VISCOUS versus ZYNRELEF KIT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: XYLOCAINE VISCOUS versus ZYNRELEF KIT.
XYLOCAINE VISCOUS vs ZYNRELEF KIT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Lidocaine is an amide-type local anesthetic that blocks voltage-gated sodium channels, inhibiting nerve impulse propagation and reducing pain sensation.
Zynrelef is a fixed-dose combination of bupivacaine and meloxicam. Bupivacaine blocks sodium channels in neuronal membranes, inhibiting nerve impulse conduction. Meloxicam inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis and inflammation.
Adults: 5-15 mL orally (or swish and spit) 4-6 times daily, not to exceed 4 doses in 12 hours or 30 mL in 12 hours.
Instillation into the surgical site: 20 mL (300 mg bupivacaine and 9.3 mg meloxicam) as a single dose.
None Documented
None Documented
Terminal elimination half-life: 1.5-2 hours in adults; prolonged in hepatic impairment or heart failure (up to 6-8 hours). In neonates, half-life may be 3-6 hours due to immature metabolism.
Terminal half-life of bupivacaine (component) is 3.5 hours; for meloxicam (component) is 20 hours. Clinical context: bupivacaine half-life prolonged in hepatic impairment; meloxicam half-life prolonged in elderly (up to 25 hours)
Renal excretion of metabolites: ~90%. Unchanged drug: <10%. Biliary/fecal: minor.
Renal: 70% unchanged; biliary/fecal: 20% as metabolites; 10% other
Category C
Category C
Local Anesthetic
Local Anesthetic and NSAID Combination